BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23824644)

  • 21. European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results from the treatment of mucosal cancers.
    Plaschke CC; Bertino G; McCaul JA; Grau JJ; de Bree R; Sersa G; Occhini A; Groselj A; Langdon C; Heuveling DA; Cemazar M; Strojan P; Leemans CR; Benazzo M; De Terlizzi F; Wessel I; Gehl J
    Eur J Cancer; 2017 Dec; 87():172-181. PubMed ID: 29156298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Involvement of c-Fos in the Promotion of Cancer Stem-like Cell Properties in Head and Neck Squamous Cell Carcinoma.
    Muhammad N; Bhattacharya S; Steele R; Phillips N; Ray RB
    Clin Cancer Res; 2017 Jun; 23(12):3120-3128. PubMed ID: 27965308
    [No Abstract]   [Full Text] [Related]  

  • 23. The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis.
    Zhou C; Shen Z; Ye D; Li Q; Deng H; Liu H; Li J
    Cell Physiol Biochem; 2018; 50(3):868-882. PubMed ID: 30355925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma.
    Hogg RP; Honorio S; Martinez A; Agathanggelou A; Dallol A; Fullwood P; Weichselbaum R; Kuo MJ; Maher ER; Latif F
    Eur J Cancer; 2002 Aug; 38(12):1585-92. PubMed ID: 12142046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer.
    Misawa K; Misawa Y; Kanazawa T; Mochizuki D; Imai A; Endo S; Carey TE; Mineta H
    Clin Exp Metastasis; 2016 Feb; 33(2):187-95. PubMed ID: 26572146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of p53 functional activity in tumor cells and histologically normal mucosa from patients with head and neck squamous cell carcinoma.
    Van der Vorst S; Dekairelle AF; Weynand B; Hamoir M; Gala JL
    Head Neck; 2012 Nov; 34(11):1542-50. PubMed ID: 22109999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic value of glycerol-3-phosphate dehydrogenase 1-like expression in head and neck squamous cell carcinoma.
    Feng Z; Li JN; Wang L; Pu YF; Wang Y; Guo CB
    Histopathology; 2014 Feb; 64(3):348-55. PubMed ID: 24274692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of gene methylation in human papillomavirus associated-head and neck squamous cell carcinoma.
    Zhang HZ; Shan CG; Huang AP; Wang JM
    Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
    Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
    J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications.
    Tabor MP; Brakenhoff RH; van Houten VM; Kummer JA; Snel MH; Snijders PJ; Snow GB; Leemans CR; Braakhuis BJ
    Clin Cancer Res; 2001 Jun; 7(6):1523-32. PubMed ID: 11410486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin.
    Califano J; Westra WH; Koch W; Meininger G; Reed A; Yip L; Boyle JO; Lonardo F; Sidransky D
    J Natl Cancer Inst; 1999 Apr; 91(7):599-604. PubMed ID: 10203278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA Methylation as a Diagnostic, Prognostic, and Predictive Biomarker in Head and Neck Cancer.
    Liouta G; Adamaki M; Tsintarakis A; Zoumpourlis P; Liouta A; Agelaki S; Zoumpourlis V
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Head and neck squamous cell carcinoma: mismatch repair immunohistochemistry and promoter hypermethylation of hMLH1 gene.
    Tawfik HM; El-Maqsoud NM; Hak BH; El-Sherbiny YM
    Am J Otolaryngol; 2011; 32(6):528-36. PubMed ID: 21353335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA global hypomethylation in squamous cell head and neck cancer associated with smoking, alcohol consumption and stage.
    Smith IM; Mydlarz WK; Mithani SK; Califano JA
    Int J Cancer; 2007 Oct; 121(8):1724-8. PubMed ID: 17582607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel.
    Ley J; Wildes TM; Daly K; Oppelt P; Adkins D
    Med Oncol; 2017 Feb; 34(2):28. PubMed ID: 28078561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of molecular alterations in histologically negative surgical margins of head and neck cancer patients.
    de Carvalho AC; Kowalski LP; Campos AH; Soares FA; Carvalho AL; Vettore AL
    Oral Oncol; 2012 Mar; 48(3):240-8. PubMed ID: 22104250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term culture of tumour slices reveals the heterogeneous sensitivity of human head and neck squamous cell carcinoma to targeted therapies.
    Donnadieu J; Lachaier E; Peria M; Saidak Z; Dakpe S; Ikoli JF; Chauffert B; Page C; Galmiche A
    BMC Cancer; 2016 Apr; 16():273. PubMed ID: 27085492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Independent evaluation of a FOXM1-based quantitative malignancy diagnostic system (qMIDS) on head and neck squamous cell carcinomas.
    Ma H; Dai H; Duan X; Tang Z; Liu R; Sun K; Zhou K; Chen H; Xiang H; Wang J; Gao Q; Zou Y; Wan H; Teh MT
    Oncotarget; 2016 Aug; 7(34):54555-54563. PubMed ID: 27409343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.
    Suenaga Y; Kitajima K; Ishihara T; Sasaki R; Otsuki N; Nibu K; Minamikawa T; Kiyota N; Sugimura K
    Eur Radiol; 2016 Apr; 26(4):1018-30. PubMed ID: 26188656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Dunn LA; Fury MG; Xiao H; Baxi SS; Sherman EJ; Korte S; Pfister C; Haque S; Katabi N; Ho AL; Pfister DG
    Ann Oncol; 2017 Oct; 28(10):2533-2538. PubMed ID: 28961834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.